Market Research Report : Cardiovascular Pharmaceuticals Market in India 2014 - Sample

Cardiovascular Pharmaceuticals Market - India

June 2014

http://www.netscribes.com/


2CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT

Drivers: Increasing patient base

Patent expiry of blockbuster drugs

Increasing disposable income

Introduction of new drugs

Drug regulation and patents

Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20-- The market is expected to grow at a CAGR of y% from 20----- CVD segment is the second largest contributor to domestic sales, contributing around x %

Challenges: Strong competition

Competition from complementary and alternative medicines

Drug value chain Phases of clinical trial Approval and licensing of drugs Patent approvals

Competition

Highly fragmented market with large number of players

Drivers and Challenges

Market

Executive Summary

Government initiatives

Reduction in drug prices

Changes in tax structure

Control Programmes

Major Public Companies Major Private Companies

Company 1 Company 4 Company 7 Company 10



Company 1 Company 4

Company 2

Company 3

Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20-- The market is expected to grow at a CAGR of y% from 20----- CVD segment is the second largest contributor to domestic sales, contributing around x %

Market



3

•Macro-Economic Indicators

•Introduction

•Market Overview

•Market Value Chain

•Drivers & Challenges

•Government Initiatives

•Regulation and Patents

•Competitive Landscape

•Recent Developments

•Strategic Recommendations

•Appendix

CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT



4

Indian cardiovascular pharma market is expected to witness huge growth in the coming years

Indian Market – Overview Market Size and Growth

Source:

0

50

100

150

INR bn

y%

2015e

x6

2014e

x5

2013e

x4

2012e

x3

2011e

x2

2010

x 1

Top Pharmaceutical Segments – 20--

0 2 4 6 8 10 12 14 16 18

%

oncology Y 10urology y 9

gynaecology Y 8pain y 7

diabetes Y 6respiratory Y 5

CNS Y 4gastro Y 3

CVD Y 2anti-infectives Y 1

• Cardiovascular therapeutic segment belongs to the

chronic segment (comprising of cardiovascular, anti

diabetics and neuro pshychiatry), which together

account for around A% of the total pharma market

• Cardiovascular segment is the second largest

contributor to domestic pharmaceuticals market

sales, with a share of x%

Within the cardiovascular segment, antihypertensive drugs

account for almost m% of revenue

Cholesterol lowering drugs account for one third of sales

• Presently the market has a size of INR X bn and is

expected to grow at a CAGR of y% from 20-- to 20-- to

reach INR Y bn

• Annually, B million Indians die of cardiovascular

diseases

• According to WHO estimates, by 2020, almost a% of

cardiac patients worldwide will be Indian




5

Drivers & Challenges - Summary

Drivers

Increasing patient base

Patent expiry of blockbuster drugs

Increasing disposable income

Introduction of new drugs

Challenges

Strong competition

Competition from complementary and alternative medicines




6

Government Initiatives – Summary

GovernmentInitiatives

Reduction in drug prices

Control programs Changes in tax structure




7

Porter’s Five Forces Analysis

Competitive Rivalry• Texttext texttext texttext texttext

texttext texttext• Texttext texttext texttext texttext


texttext texttext

Bargaining Power of Buyers• Texttext texttext texttext

texttext texttext texttext• Texttext texttext texttext

texttext texttext texttext• Texttext texttext texttext

texttext texttext texttext

Threat of New Entrants• Texttext texttext texttext texttext



texttext texttext ImpactLow to

Medium

ImpactMedium to

High

ImpactHigh

Bargaining Power of Suppliers• Texttext texttext texttext texttext



texttext texttext

ImpactLow to

Medium

Threat of Substitutes• Texttext texttext texttext texttext



texttext texttext

ImpactLow

SAMPLE




8

Competitive Benchmarking (1/5)

Public Trading Comparables (FY 20--) – Top 4 Companies


Market Capitalization (xx)

Share Price (xx)

EV/EBITDA (xx)

EV/Revenue (xx)

PE Ratio

Note: Top 3 Public companies based on the Market Capitalization, Share Price and PE ratio is as of 24/03/2014




9

Public: Domestic Company – A Company (1/4)

Key People

Products and Services

Company Information Offices and Centres – India

Corporate AddressX RoadBangalore

Tel No. +91 xx xxxxx xxxxx

Fax No. +91 xx xxxxx xxxxx

Website www.ppp.com

Year of Incorporation 19--

Ticker Symbol xxxxxx

Stock Exchange NNN

Name Designation

Person M Founder

Person N CFO

Person O Head

Person Q President

City A Products and ServicesHead Office

Source:

Category Products/Services

PharmaceuticalCVD, CNS, respiratory, dermatology, orthopedics, nutritional, urology, anti-infectives

Molecule Development

Infectious diseases, metabolic diseases, inflammatory/respiratory diseases, and oncology




http://www.ppp.com/

10

Source:

Key Ratios

Financial Summary


• The company incurred a net loss of INR xx mn in FY 20--, as compared to net profit of INR yy mn in FY 20--

• The company reported total income of INR xx bn in FY 20--, registering an increase of yy per cent over FY 20--

• The company earned an operating margin of x per cent in FY 20-- a decrease of y percentage points over FY 20--

• The company reported debt to equity ratio of x in FY 20--, an increase of y per cent over FY 20--

Financial Summary

Profit / Loss

RevenueProfit

INR mn

p

n

0

-m

RevenueINR mn

0

20--

tp

20--

s

o

20--

r

n

20--

q

m

10,000

5,000

Indicators Present Value

Market Capitalization (INR) X units

Total Enterprise Value (INR) Y units

EPS (INR) Z units

PE Ratio (Absolute) A

Particulars y-o-y change 20-- 20-- 20-- 20--

Profitability RatiosOperating Margin

Net Margin

Profit Before Tax Margin

Return on Equity

Return on Capital Employed

Return on Working Capital

Return on Assets

Return on Fixed Assets

Cost RatiosOperating costs (% of Sales)

Administration costs (% of Sales)

Interest costs (% of Sales)

Liquidity RatiosCurrent Ratio

Cash Ratio

Leverage RatiosDebt to Equity Ratio

Debt to Capital Ratio

Interest Coverage Ratio

Efficiency RatiosFixed Asset Turnover

Asset Turnover

Current Asset Turnover

Working Capital Turnover

Capital Employed Turnover

Improved Decline

Financial Snapshot




11


y

x

20--

z y

x

20--

z y

x

20--

zy

x

20--

z

onm

Key Business Segments

20--

z

y

x

20--

z

y

x

20--

z

y

x

20--

z

y

x

x y z

Key Geographic Segments

Source:

Key Recent Developments

Description News

Overview• Company A is an integrated research based company that produces a wide range of generic medicines

• Serves customers in over 100 countries with manufacturing facilities in several countries

Cardiovascular Pharmaceuticals

• Products include include Product 1 and Product 2

Key Initiatives• Is making consistent effort for continual improvement in rural areas with respect to accessibility of

medicines




12

Public: Foreign Company – XX (4/4)

• Texttext texttext texttext texttext texttext texttext








• .




TO

WS





Private: Domestic Company – XXXXX XXXXX Ltd. (1/5)

Key People

Products and Services

Company Information Offices and Centres – India

Corporate Address

Xxxxx xxxxxx xxxxxxxxxxx Roadxxxxxxxxx 3--------Gujarat

Tel No. +91 xx xxxx xxxx

Fax No. +91 xx xxxx xxxx

Website www.hhh.com

Year of Incorporation 19--

Category Products/Services

Pharmaceutical Products

Therapeutic areas like neurology, psychiatry, cardiology, pain management, gastroenterology etc.

BiotechnologyChronic diseases like oncology and nephrology by subsidiary Intas Biopharmaceuticals Ltd.

Name Designation

Person 1 Founder and Chairman

Person 2 MD

Person 3 CFO

Head Office

City A



http://www.intaspharma.com/

14


Shareholders of the Company Ownership Structure

Name No. of Shares held

Shareholder 1 47,---,---,---

Shareholder 2 11,---,---







Total 114,---,---

Note: Shareholding pattern as on AGM dated 31st Mar 2013

16.2%

46.4%

37.5%

Xxxxxx xxxxxxx xxxxx

Xxxxxx xxxxxx

Xxxxxxxx xxxxxx





Financial Snapshot Key Ratios

Financial Summary

• The company incurred a net loss of INR xx mn in FY 20--, as compared to net profit of INR yy mn in FY 20--

• The company reported total income of INR xx bn in FY 20--, registering an increase of yy per cent over FY 20--

• The company earned an operating margin of x per cent in FY 20-- a decrease of y percentage points over FY 20--

• The company reported debt to equity ratio of x in FY 20--, an increase of y per cent over FY 20--

Particulars y-o-y change

(2013-12)2013 2012 2011 2010

Profitability RatiosOperating Margin

Net Margin

Profit Before Tax Margin

Return on Equity

Return on Capital Employed

Return on Working Capital

Return on Assets

Return on Fixed Assets

Cost RatiosOperating costs (% of Sales)

Administration costs (% of Sales)

Interest costs (% of Sales)

Liquidity RatiosCurrent Ratio

Cash Ratio

Leverage RatiosDebt to Equity Ratio

Debt to Capital Ratio

Interest Coverage Ratio

Efficiency RatiosFixed Asset Turnover

Asset Turnover

Current Asset Turnover

Working Capital Turnover

Capital Employed Turnover

Improved Decline


Profit / Loss

RevenueProfit

INR mn

p

n

0

-m

RevenueINR mn

0

20--

tp

20--

s

o

20--

r

n

20--

q

m

10,000

5,000




Business Highlights

Description News

Overview

• Is a vertically integrated global pharmaceutical formulation development company involved in manufacturing and marketing

• Operates 4 subsidiaries operating in different business segments • Has presence in over xx countries with successful contract manufacturing and contract

marketing tie-ups across the world predominantly in xx, yy and zz

Cardiovascular Pharmaceutical

• Has T products in its xx product segment under M10, N, O and P brand names

• Has xx products in its RR product segment under brand names like A, B, C, D, E, F, G, Q, R, S, T, U, V, W, X, Y, and Z

Key initiatives• XXX received an outstanding review for itself for developmental works like The Y Project

scholarships for students and V Journals





Private: Domestic Company – XXXXX XXXXX Ltd. – SWOT Analysis (5/5)












TO

WS




Thank you for the attention

About Netscribes, Inc.Netscribes, Inc. is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes, Inc. is a one-stop shop designed to fulfil clients’ profitability and growth objectives.

Cardiovascular Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Series. For any queries or customized research requirements, contact us at:

Disclaimer: This report is published for general information only. Although high standards have been used in the preparation, “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes and prior permission is required for guidelines on reproduction.

Phone: +91 22 4098 7600E-Mail: [email protected]





mailto:[email protected]

Date post:	08-May-2015
Category:	Business
Upload:	netscribes-inc
View:	741 times
Download:	1 times